Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users

被引:19
作者
Wetherell, Mark A. [1 ]
Montgomery, Catharine [2 ]
机构
[1] Northumbria Univ, Dept Psychol, Hlth Act Stress Res Grp, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England
[2] Liverpool John Moores Univ, Sch Nat Sci & Psychol, Liverpool L3 5UX, Merseyside, England
关键词
MDMA; Ecstasy; Cortisol; HPA axis; Cortisol awakening response; CORTISOL AWAKENING RESPONSE; MDMA ECSTASY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; MEMORY DEFICITS; STRESS; CANNABIS; TIME; ECSTASY/POLYDRUG; NEUROENDOCRINE; EXPERIENCES;
D O I
10.1007/s00213-013-3325-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users. The current study is the first to explore the effects of ecstasy-polydrug use on psychological distress and basal functioning of the HPA axis through assessing the secretion of cortisol across the diurnal period. Seventy-six participants (21 nonusers, 29 light ecstasy-polydrug users, 26 heavy ecstasy-polydrug users) completed a substance use inventory and measures of psychological distress at baseline, then two consecutive days of cortisol sampling (on awakening, 30 min post awakening, between 1400 and 1600 hours and pre bedtime). On day 2, participants also attended the laboratory to complete a 20-min multitasking stressor. Both user groups exhibited significantly greater levels of anxiety and depression than nonusers. On day 1, all participants exhibited a typical cortisol profile, though light users had significantly elevated levels pre-bed. On day 2, heavy users demonstrated elevated levels upon awakening and all ecstasy-polydrug users demonstrated elevated pre-bed levels compared to non-users. Significant between group differences were also observed in afternoon cortisol levels and in overall cortisol secretion across the day. The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.
引用
收藏
页码:1365 / 1375
页数:11
相关论文
共 80 条
[1]   Flattened cortisol rhythms in metastatic breast cancer patients [J].
Abercrombie, HC ;
Giese-Davis, J ;
Sephton, S ;
Epel, ES ;
Turner-Cobb, JM ;
Spiegel, D .
PSYCHONEUROENDOCRINOLOGY, 2004, 29 (08) :1082-1092
[2]   Seasonal effects on cortisol secretion in normal aging, mild cognitive impairment and Alzheimer's disease [J].
Arsenault-Lapierre, Genevieve ;
Chertkow, Howard ;
Lupien, Sonia .
NEUROBIOLOGY OF AGING, 2010, 31 (06) :1051-1054
[3]   Diurnal cortisol rhythm and fatigue in breast cancer survivors [J].
Bower, JE ;
Ganz, PA ;
Dickerson, SS ;
Petersen, L ;
Aziz, M ;
Fahey, JL .
PSYCHONEUROENDOCRINOLOGY, 2005, 30 (01) :92-100
[4]   Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern? [J].
Boyle, Noreen T. ;
Connor, Thomas J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (01) :17-32
[5]   Circadian regulation of cortisol after hippocampal damage in humans [J].
Buchanan, TW ;
Kern, S ;
Allen, JS ;
Tranel, D ;
Kirschbaum, C .
BIOLOGICAL PSYCHIATRY, 2004, 56 (09) :651-656
[6]   Altered responsiveness of the hypothalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis [J].
Buske-Kirschbaum, A ;
Geiben, A ;
Höllig, H ;
Morschhäuser, E ;
Hellhammer, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) :4245-4251
[7]   Preliminary Evidence for Lowered Basal Cortisol in a Naturalistic Sample of Methamphetamine Polydrug Users [J].
Carson, Dean S. ;
Bosanquet, David P. ;
Carter, C. Sue ;
Pournajafi-Nazarloo, Hossein ;
Blaszczynski, Alex ;
McGregor, Iain S. .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2012, 20 (06) :497-503
[8]  
Cole J, 2002, PSYCHOLOGIST, V15, P464
[9]   Methylenedioxymethamphetamine suppresses production of the proinflammatory cytokine tumor necrosis factor-α independent of a β-adrenoceptor-mediated increase in interleukin-10 [J].
Connor, TJ ;
Harkin, A ;
Kelly, JP .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (01) :134-143
[10]  
Department of Health, 2010, UK DRUG SIT ANN REP